Cancer diagnostics market analysis and updates

The global cancer burden is increasing. With precision oncology entering mainstream care, more patients are undergoing biomarker testing in order to access more targeted and effective therapies. 

Clearstate offers market data, forecasts, and trend predictions to give you insight on the fast-growing cancer diagnostics market. Our cancer diagnostics hub is regularly updated to share our findings on the current state of cancer diagnostics and the impact of developments such as a growing global cancer burden and the rise of precision care on the future of cancer IVDs.

Cancer diagnostics updates

What are cancer diagnostics?

Cancer diagnostics or lab tests used in cancer diagnosis range from tissue-based tests to molecular testing. Today, a wide range of cancer in vitro diagnostics (IVD) tests are available, including immunoassays, tissue-based tests, PCR-based molecular diagnostics, liquid biopsy and next generation sequencing (NGS).

Explore the latest cancer testing market insights

From market news to analysis, our articles provide concise and up-to-date information about latest diagnostic innovations which are opening up new possibilities for cancer testing and treatment. Uncover the challenges and opportunities ahead as laboratories play a key role in combating the rising global cancer burden. 

What are the infrastructure, reimbursement levels, affordability and availability of cancer IVDs that influence the access to cancer IVDs in each country or region? How is the patient journey for cancer diagnosis and treatment using biomarkers changing? What are the top cancer biomarkers and test strategies?

Understand the cancer diagnostics market

Discover more IVD insights and learn how our IVD Gateway solution can help prepare your business to support the drive to integrate the use of IVDs into regional or national plans to fight cancer.

Clearstate newsletter

Sign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts.